AbbVie (NYSE:ABBV) had its target price decreased by stock analysts at Barclays from $120.00 to $102.00 in a note issued to investors on Thursday. The brokerage currently has an “equal weight” rating on the stock. Barclays’ target price indicates a potential upside of 13.61% from the stock’s current price.
A number of other brokerages also recently commented on ABBV. Credit Suisse Group set a $135.00 target price on shares of AbbVie and gave the stock a “hold” rating in a research note on Monday, January 29th. Leerink Swann cut shares of AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 price target for the company. in a research report on Monday, January 29th. Jefferies Group set a $145.00 price target on shares of AbbVie and gave the company a “buy” rating in a research report on Monday, February 26th. BMO Capital Markets set a $84.00 price target on shares of AbbVie and gave the company a “hold” rating in a research report on Thursday, January 11th. Finally, Zacks Investment Research cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. AbbVie presently has an average rating of “Buy” and an average price target of $117.38.
Shares of ABBV stock opened at $89.78 on Thursday. The company has a debt-to-equity ratio of 6.07, a current ratio of 1.28 and a quick ratio of 1.18. The firm has a market cap of $147,586.22, a P/E ratio of 16.03, a PEG ratio of 0.88 and a beta of 1.61. AbbVie has a 12 month low of $63.12 and a 12 month high of $125.86.
AbbVie announced that its Board of Directors has approved a share repurchase plan on Thursday, February 15th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.
In other news, VP Robert A. Michael sold 4,294 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $119.43, for a total value of $512,832.42. Following the completion of the sale, the vice president now directly owns 11,170 shares of the company’s stock, valued at $1,334,033.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert A. Michael sold 992 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $120.31, for a total transaction of $119,347.52. The disclosure for this sale can be found here. Insiders sold 211,197 shares of company stock valued at $24,585,575 over the last ninety days. Corporate insiders own 0.07% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Ffcm LLC raised its holdings in AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after purchasing an additional 963 shares in the last quarter. Bristlecone Advisors LLC purchased a new position in AbbVie during the third quarter worth about $113,000. Truewealth LLC purchased a new position in AbbVie during the fourth quarter worth about $126,000. Delpha Capital Management LLC purchased a new position in AbbVie during the fourth quarter worth about $131,000. Finally, Hershey Trust Co. purchased a new position in AbbVie during the third quarter worth about $139,000. 70.54% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Barclays Trims AbbVie (ABBV) Target Price to $102.00” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3337058/barclays-trims-abbvie-abbv-target-price-to-102-00.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.